Literature DB >> 17568207

Current concepts and techniques in pterygium treatment.

Leonard P K Ang1, Jocelyn L L Chua, Donald T H Tan.   

Abstract

PURPOSE OF REVIEW: Pterygium is a common ocular disorder in many parts of the world. At present, there is a wide variety of surgical methods but very few clinical guidelines on the optimal treatment of primary or recurrent pterygium. The purpose of this review is to summarize the more recent and relevant studies on pterygium treatment. RECENT
FINDINGS: The primary aim is to excise the pterygium and prevent its recurrence. As bare sclera excision is associated with a high recurrence rate, pterygium excision is often combined with conjunctival autograft, mitomycin C, beta-irradiation or other adjunctive therapies to reduce recurrence rates. There is currently, however, no consensus regarding the ideal treatment for the disease. Comparability between studies is also hampered by the various definitions of pterygium recurrence.
SUMMARY: This article reviews the current concepts and techniques used for the treatment of pterygium. Conjunctival autografting and mitomycin C application are the most commonly used methods for preventing recurrences. The use of mitomycin C and beta-irradiation should be used judiciously because of the potential long-term risk of sight-threatening complications. Additional clinical trials should be performed to evaluate the relative efficacies and long-term safety of the various treatment modalities.

Entities:  

Mesh:

Year:  2007        PMID: 17568207     DOI: 10.1097/ICU.0b013e3281a7ecbb

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  52 in total

1.  Triple subconjunctival bevacizumab injection for early corneal recurrent pterygium: one-year follow-up.

Authors:  Angel Nava-Castañeda; Isabel Ulloa-Orozco; Lilia Garnica-Hayashi; Joaquín Hernandez-Orgaz; Maria Carmen Jimenez-Martinez; Yonathan Garfias
Journal:  J Ocul Pharmacol Ther       Date:  2014-11-04       Impact factor: 2.671

2.  Sutureless amniotic membrane transplantation combined with narrow-strip conjunctival autograft for pterygium.

Authors:  Hande Taylan Sekeroglu; Elif Erdem; Nese Cetin Dogan; Meltem Yagmur; Reha Ersoz; Ahmet Dogan
Journal:  Int Ophthalmol       Date:  2011-12-07       Impact factor: 2.031

3.  New approach for pterygium removal using 20 % ethanol.

Authors:  Erez Tsumi; Jaime Levy; Anry Pitchkhadze; Amjad Baidousi; Tova Lifshitz
Journal:  Int Ophthalmol       Date:  2012-06-21       Impact factor: 2.031

Review 4.  [Operative techniques for surgical treatment of primary and recurrent pterygia].

Authors:  W Sekundo; K Droutsas; C Cursiefen
Journal:  Ophthalmologe       Date:  2010-06       Impact factor: 1.059

5.  [Pterygium. Etiology, clinical aspects and novel adjuvant therapies].

Authors:  L M Heindl; C Cursiefen
Journal:  Ophthalmologe       Date:  2010-06       Impact factor: 1.059

6.  [Pterygium surgery. Complication following adjuvant radiotherapy].

Authors:  C Lange; D Böhringer; T Reinhard
Journal:  Ophthalmologe       Date:  2010-08       Impact factor: 1.059

7.  Conjunctival limbal autograft transplantation in pterygium surgery by natural haemostasis.

Authors:  Sonali V Kumar; Shrikant Waikar; V K Srivastava
Journal:  Med J Armed Forces India       Date:  2013-05-09

8.  Ophthalmic pterygium: a stem cell disorder with premalignant features.

Authors:  Jeanie Chui; Minas T Coroneo; Lien T Tat; Roger Crouch; Denis Wakefield; Nick Di Girolamo
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

9.  The study of etiological and demographic characteristics of pterygium recurrence: a consecutive case series study from Pakistan.

Authors:  P Salim Mahar; Nabeel Manzar
Journal:  Int Ophthalmol       Date:  2013-06-18       Impact factor: 2.031

10.  Risk factors for pterygium recurrence after limbal-conjunctival autografting: a retrospective, single-centre investigation.

Authors:  Naser Samadi Aidenloo; Qader Motarjemizadeh; Maryam Heidarpanah
Journal:  Jpn J Ophthalmol       Date:  2018-03-16       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.